Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver
- Details
- Category: EASL 2011
- Published on Tuesday, 05 July 2011 21:51
- Written by Liz Highleyman
March 30 - April 3, 2011, Berlin, Germany
The material posted on HIVandHepatitis.com is not approved by nor is it a part of EASL 2011.
Hepatitis C Articles
- EASL Releases New Hepatitis C Clinical Practice Guidelines
- Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
- Tegobuvir Works Well in Triple and Quad Regimens for HCV
- Boosted Danoprevir Improves Response in Prior Null Responders
- Once-Daily BI201335 Ups Response to Interferon for Hepatitis C
- BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- Statin Boosts Response to Pegylated Interferon/Ribavirin
- Boceprevir Helps Hepatitis C Patients with Cirrhosis
- TMC435 Beats Standard Therapy Regardless of HCV Genotype
- Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Pegylated Interferon Lambda Boosts Response with Few Side Effects
- First Sustained Response Data for Polymerase Inhibitor Mericitabine
- 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
- Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
- BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
- Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab
Hepatitis B Articles
- Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
- HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
- Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
Library of Slides and Posters
-
Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment
J Heathcote and others. EASL 2011. -
Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist
D Tumas and others. EASL 2011. -
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
R Lanford and others. EASL 2011. -
Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection
S Menne and others. EASL 2011. -
Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study
J Aerssens and others. EASL 2011. -
Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin
O Lenz and others. EASL 2011. -
Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment
V Sekar and others. EASL 2011. -
The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
S Zeuzem and others. EASL 2011. -
First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects
S Pol and others. EASL 2011. -
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
E Lawitz and others. EASL 2011. -
Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB
L Tepperman and others. EASL 2011. -
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
A Corsa and others. EASL 2011. -
Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB)
S Fung and others. EASL 2011. -
Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
P Marcellin and others. EASL 2011. -
A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects
U Lopatin and others. EASL 2011. -
HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years
P Marcellin and others. EASL 2011.
EASL Releases New Hepatitis C Clinical Practice Guidelines
- Details
- Category: HCV Treatment Guidelines
- Published on Friday, 06 May 2011 14:45
- Written by EASL
EASL updates European guidelines for management of patients with acute and chronic hepatitis C virus (HCV) infection.
EASL 2011: HIV/HCV Coinfection among HIV Positive Gay Men
- Details
- Category: HIV/HCV Coinfection
- Published on Saturday, 23 April 2011 14:33
- Written by Liz Highleyman
Researchers at EASL presented further data on outbreaks of sexually transmitted HCV among HIV positive men who have sex with men. Sustained response rates are high when interferon-based therapy is started during acute infection, but re-infection after treatment is common in this population.
EASL 2011: Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 25 April 2011 23:54
- Written by Liz Highleyman
Addition of the experimental HCV protease inhibitor ABT-450, boosted with ritonavir, to standard therapy increased the likelihood of complete early virological response at 12 weeks in previously untreated genotype 1 chronic hepatitis C patients.
EASL 2011: Tegobuvir Works Well in Triple and Quad Regimens for HCV
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 23 April 2011 13:56
- Written by Liz Highleyman
Gilead's HCV polymerase inhibitor tegobuvir (GS-9190) improved response rates in treatment-naive genotype 1 patients when used in various combinations with pegylated interferon, ribavirin, and the experimental protease inhibitor GS-9256, researchers reported at EASL 2011.